Other · developed by Veradermics
VDMN-21 is a microneedle patch containing an active drug at 125 mcg or 250 mcg per patch. It is studied in verruca vulgaris (common warts).
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05799157 | Phase 2 | Verruca Vulgaris | Completed | MANE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Common WartVerruca VulgarisWarts
Updated Oct 18, 2026. Something wrong or missing? Report it on the MANE page.
See MANE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MANE catalysts and pipeline →